Already, there is an expectation that Merck will be able to gain pricing and marketing advantages because it sells the current standard of care drugs, ribavirin and pegylated interferon.
The motives behind its fierce opposition to the Wyden-Ryan premium-support proposal illustrate further advantages to moving from administrative to competitive pricing in Medicare.